VivoSeq
Other

Cognitive Functions

0

Pipeline Programs

1

Active Trials

2

Companies Involved

Cognitive Functions is an early-stage landscape with 0 programs across 2 companies. The most active players are Ipsen, Sanofi.

Pipeline Metrics

Competitive Density

6/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Programs by Phase

No pipeline programs currently tracked for this disease.

Trial Status

16

clinical trials

Completed12 · 75%
Unknown status3 · 19%
Not yet recruiting1 · 6%

Trial Activity

16 trials

Cognitive Functions After TIVA With Dexmedetomidine
Completed·UUludag University·Phase 4·NCT02631135·40 enrolled
Changes in Cerebral Oxygenation and Cognitive Functions
Completed··N/A·NCT04948957·40 enrolled
Efficacy Study on Cognitive Functions in Schizophrenic Patients
Completed·Sanofi logoSanofi·Phase 4·NCT00761670·37 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)